Q&A with Rexahn CEO Dr. Peter Suzdak on the Next Generation of Targeted Cancer Drugs

The most widely used drugs in the arsenal against cancer today, chemotherapies, can be effective in destroying tumors due to their broad anti-cancer activity, however they also destroy the immune system and tumors can quickly become resistant to chemotherapy. Emerging immunotherapies like PD1 and CAR T-cell drugs offer the advantage of being effective against tough cancers, but their safety profiles are worrisome.

– The Bio Connection –

Click here for more information